Effects on blood coagulation of adjuvant CNF (cyclophosphamide, novantrone, 5-fluorouracil) chemotherapy in stage II breast cancer patients

Anticancer Research

Volumn 19, Issue 4 C, 1999, Pages 3521-3526

  Pectasides, D ^a   Tsavdaridis, D ^b   Aggouridaki, Ch ^b   Tsavdaridou, V ^b   Visvikis, A ^a   Tsatalas, K ^c   Fountzilas, G ^b  

^a METAXA CANCER HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Metaxas Memorial Cancer Hospital ^*

Author keywords

Blood coagulation; Chemotherapy

Indexed keywords

ANTITHROMBIN III; CYCLOPHOSPHAMIDE; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FLUOROURACIL; MITOXANTRONE; PROTEIN C; PROTEIN S;

ADULT; AGED; ARTICLE; BLOOD CLOTTING DISORDER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG SAFETY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; RISK FACTOR; THROMBOCYTE COUNT; THROMBOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTITHROMBIN III; BLOOD COAGULATION; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; FEMALE; FIBRINOGEN; FLUOROURACIL; HUMANS; MIDDLE AGED; MITOXANTRONE; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBOPLASTIN; TIME FACTORS;

EID: 0033428958     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Trousseau A: Phlegmasia alba dolens. Clin Med Hotel Dieu de Paris 3: 94, 1865.
2. Rickles FR, Levine MN, Edwards RL: Haemostatic alterations in cancer patients. Cancer Metast Rev 11: 237-248, 1992.
3. Falanga A, Barbui T, Rickles FR, Levine MN: Guidelines for clotting studies in cancer patients Thromb Haemost 70: 343-350, 1993.
4. Weiss RB, Tormey DC, Holland JF, Weinberg VE: Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep 65: 677-679, 1981.
5. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk K, de Pauw S: The thrombogenic effect of anticancer drug therapy in women with Stage II breast cancer. N Engl J Med 318: 404-407, 1988.
6. Saphner T, Tormey DC, Gray R: Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9: 286-294, 1991.
7. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH: Increased incidence of thromboembolism in Stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 54: 1264-1268, 1984.
8. Tempelhoff GFV, Dietrich M, Hommel G, Heilmann L: Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol 14: 2560-2568, 1996.
9. Fisher B, Constantino J, Redmond C, Poisson R, Bowman D, Conture J, Dimitrov NW, Wolmark N, Wickerham DL, Fisher ER, Margolese R, Robidoux A, Shibato H, Terz J, Paterson AHG, Feldman MI, Farrar W, Evans J, Lickley HL, Ketner M, and others: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node- negative breast cancer who have estrogen -receptor - positive tumors. N Enlg J Med 320: 479-484, 1989.
10. Enck RE, Rios CN: Tamoxifen treatment of metastatic breast cancer and antithrombin III levels. Cancer 53: 2607-2609, 1984.
11. Pectasides D, Barbounis V, Athanassiou A, Mariatos P: Cerebrovascular accidents following hormonotherapy in cancer patients. Am J Clin Oncol 15: 168-173, 1992.
12. Luzzatto G, Schafer A: The prethrombotic state in cancer. Semin Oncol 17: 147-159, 1990.
13. Bick RL: Alteration of hemostasis associated with malignancy. Semin Thromb Hemost 5: 1-26, 1978.
14. Komp DM, Lyles RL, Boyd TH, et al: The effect of cancer chemotherapeutic agents on fibrin formation and stabilization in vitro. Pediatr Res 8: 75-81, 1974.
15. Rogers JS, Murgo AJ, Fontana JA, Raich PC: Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 6: 276-281, 1988.
16. Feffer SE, Carmosino LS, Fox RL: Acquired Protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer 63: 1303-1307, 1989.
17. Orr FW, Adamson IYR, Young L: Promotion of pulmonary metastasis in mice by bleomycin - induced endothelial injury. Cancer Res 46: 891-897, 1983.
18. Nicolson GL, Custead SE: Effects of chemotherapeutic drugs on platelets and metastatic tumor cell-endothelial interactions as a model for assessing vascular endothelial integrity. Cancer Res 45: 331-336, 1985.
19. Doll DC, Ringenberg OS, Yabro JW: Vascular toxicity associated with antineoplastic drugs. J Clin Oncol 4: 1405-1417, 1986.
20. Patterson WP, Ringenberg QS: The pathophysiology of thrombosis in cancer. Semin Oncol 17: 140-146, 1990.
21. Chahwala SD, Hickmann JA: Effect of the antitumor drug adriamycin on human blood cell discocyte-echinocyte transitions. Cancer Res 45: 4986-4989, 1985.
22. Look MP, Musch E: Lipid peroxides in the polychemotherapy of cancer patients. Chemotherapy 40: 8-15, 1994.
23. Boyer C, Rothschild G, Wolf M, Amiral J, Meyer D, Larrieu M: A new method for the estimation of protein C by Elisa. Thromb Res 36: 579-589, 1984.
24. Amiral J, Adam M, Plassart V, Minard F, Vissac AM: Immunoassays for the measurement of protein S. In Fibrinolysis: current prospects. PJ Gaffrey et al. London: J Libbey Co Ldt. 125-128, 1988.
25. Montgomery DC: Design and analysis of experiments. Wiley New York, 1991.
26. Wilfrid J, Dixon, Frank J, Massey Jr: Introduction to statistical analysis. McGraw-Hill, NewYork, 1951.
27. Bartomen MC, Gallo S, Lauri D, Levine MN, Orr FW, Buchanan MR: Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exper Metastasis 8: 511-518, 1990.
28. Wheeler HR, Geczy CL: Induction of macrophage procoagulant expression cisplatin, daunorubicin and doxorubicin. Int J Cancer 46: 626-632, 1992.
29. Walsh J, Wheeler HR, Gency CL: Modulation of tissue factor on human monocytes by cisplatin and adriamycin. Br J Haematol 81: 480-488, 1992.
30. Canobbio L, Fassio T, Ardizzoni A, Bruzzi P, Queirolo MA, Zarcone D, Di Giorgio F, Rosso R, Santi L: Hypercoagulable state induced by cytostatic drugs in stage II breast cancer patients. Cancer 58: 1032-1036, 1986.
31. Edwards RL, Klaus M, Mathews E: Heparin abolishes the chemotherapy induced increase in plasma fibrinopeptide A levels. Am J Med 89: 25-28, 1990.
32. Wojtukiewicz MZ, Zacharski LR, Memoli VA: Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer 65: 516-521, 1990.
33. Rella C, Coviello M, Giotta F, Maiello E, Colovarito P, Colangelo D, Quaranta M, Colucci G, Schittuli F: A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treatm 40: 151-159, 1996.